Summary
Highlights
The first stock is CleanSpark (CLSK), a Bitcoin mining company. With Bitcoin hitting all-time highs, miner profitability is exploding. CleanSpark reported $344 million in revenue in the first half of the year. Wall Street has a price target of over $20, significantly higher than its current ~$15. The stock shows institutional money accumulation through volume spikes. An ideal entry would be a pullback to $15 or a breakout above $16.50. This is a momentum play reliant on Bitcoin's strength and involves higher risk, recommending a small position size (e.g., 25% of allocated funds).
The second stock is Oric Pharmaceuticals (ORIC), an oncology-focused biotech. Oncology dominates biotech deal-making, making it a hot sector. Unlike many high-risk biotechs, Oric has $283 million in cash and zero debt, providing a long runway for clinical trials without diluting shareholders. Eight out of ten Wall Street analysts recommend a buy, with an average price target of $17.29 from its current $11.50. The technical setup shows consolidation and recovery above its 50-day moving average. Positive clinical trial data is the main catalyst, offering potential for parabolic moves, but trials failing is a significant risk. Entry points are around $12.20 on a breakout, or later at $13 with volume confirmation for cautious investors. Position sizing remains at 25% due to the high-risk, high-reward nature.
The third stock is Regeneron Pharmaceuticals (REGN), a large-cap biotech company. It's a more stable growth anchor with multiple drugs, particularly Dupixent, which saw 23% year-over-year sales growth, bringing in nearly $4 billion last quarter. Dupixent recently secured approval for COPD, opening a massive new market. Analysts have a price target of over $1,000, presenting a 70% upside from its current $600. The entry strategy involves buying on a breakout above recent highs around $620 or on a pullback to its 50-day moving average. This stock offers lower risk but still significant upside, also recommending a 25% allocation.
The fourth stock is Lithium Argentina (LAR), a lithium mining company crucial for the EV revolution. The company is trading at 0.36 times its book value, indicating a massive discount. Lithium prices are believed to have bottomed out, and a modest rebound could lead to significant gains. LAR is ramping up production and lowering costs. While highly volatile, it's considered a longer-term play on the commodity cycle. An ideal entry would be on a pullback to around $3.70 for a discount or on a breakout above recent highs. This is a speculative play and requires careful position sizing (25% allocation) due to volatility.
The video concludes by summarizing the diversified strategy: allocating $1,000 across the four stocks (CLSK, ORIC, REGN, LAR), each receiving $250. This diversification across sectors (crypto, biotech, pharma, commodities) and market caps helps mitigate risk. The strategy emphasizes not 'betting the farm' on a single idea. The presenter also stresses the importance of setting stop-loss orders (10-20% recommended) to manage risk and protect capital from emotional decisions. The overall thesis is that money is rotating from overvalued tech to undervalued growth and commodities, making these four stocks favorable now.
The presenter, Felix Pri, an ex-investment banker, introduces four under-the-radar stock opportunities across Bitcoin mining, biotech, pharma, and lithium. He highlights why these sectors are poised for rallies, focusing on real companies with catalysts trading at attractive prices. The discussion promises to provide tickers, entry prices, catalysts, Wall Street positioning, risks, and intelligent position sizing.